Pediatr Gastroenterol Hepatol Nutr.  2023 Jul;26(4):224-229. 10.5223/pghn.2023.26.4.224.

Proven Cytomegalovirus Colitis Associated with Dasatinib Administration in Two Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients

• Kim JM
• Kang HM
• Yoo IH
• Lee DG
• Chung NG
• Cho B

• KMID: 2544885
• DOI: http://doi.org/10.5223/pghn.2023.26.4.224

Abstract

Gastrointestinal (GI) bleeding is a rare adverse event of dasatinib, which is known to be caused by dasatinib-induced colitis, severe thrombocytopenia, and platelet dysfunction. We present two cases of pediatric patients who developed hematochezia during treatment with dasatinib after hematopoietic stem cell transplantation (HSCT). A colonic tissue biopsy was performed to differentiate the cause of GI bleeding. Both patients were diagnosed with proven cytomegalovirus (CMV) colitis, but only one was treated with ganciclovir. The patient who did not receive antiviral therapy experienced recurrent GI bleeding during dasatinib administration, leading to multiple treatment interruptions. During dasatinib therapy after HSCT, patients with GI bleeding and confirmed CMV colitis may benefit from antiviral therapy to reduce interruptions in dasatinib therapy.

Keyword

Dasatinib; Cytomegalovirus; Child; Hematopoietic stem cell transplantation